K991673

MAY 2 6 1999

# Attachment 4

## Summary of Safety and Effectiveness

| | |
|---|---|
| **General Provisions** | Trade Name: Cordis Tempo™ Angiography Catheters<br>Common/Classification Name: Diagnostic Intravascular Catheter |
| **Name of Predicate Devices** | Cordis Tempo™ Angiography Catheters (K973401) |
| **Classification** | Class II. |
| **Performance Standards** | Performance standards have not been established by the FDA under section 514 of the Food, Drug and Cosmetic Act. |
| **Intended Use and Device Description** | Cordis Tempo Angiography Catheters are intended for the delivery of radiopaque contrast medium to selected sites in the vasculature.<br>The device description of Cordis Tempo Angiography Catheters is as follows:<br>The Tempo catheters are single lumen catheters consisting of Polyamide (body, intermediate and distal tip) and Polyurethane (brite tip) materials with a proximal strainrelief and hub. The catheters are available in various diameters and tip configurations. They are compatible with Guidewires with diameters of 0.035" and 0.038". |
| **Biocompatibility** | All materials used in the Tempo Angiographic Catheters are biocompatible. |
| **Summary of Substantial Equivalence** | The Cordis Tempo™ Angiography Catheters (40 to 125 cm length) are substantially equivalent to the previously cleared Cordis Tempo Catheters (65 to 125 cm length). |

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

MAY 26 1999

Ariel MacTavish, RAC
Sr. Regulatory Affairs Associate
Cordis Corporation
14201 N.W. 60th Avenue
Miami Lakes, FL 33014

Re: K991673
Trade Name: 4F Tempo™ Angiography Catheters
Regulatory Class: II
Product Code: DQO
Dated: May 14, 1999
Received: May 17, 1999

Dear Ms. MacTavish:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices

under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4586. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Thomas J. Callahan

Thomas J. Callahan, Ph.D.
Director
Division of Cardiovascular,
Respiratory and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

## Attachment 2

# Indications for Use Statement

| | |
|---|---|
| **510(k) Number** (if known) | |
| **Device Name** | Tempo ™ Angiography Catheter |
| **Indications for Use** | Cordis Tempo ™ Angiography Catheters are intended for the delivery of radiopaque contrast medium to selected sites in the vasculature. |

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular, Respiratory,
and Neurological Devices
510(k) Number K991673

Prescription Use ✓ OR Over-The-Counter Use_____
(Per 21 CFR 801.109)